Patents by Inventor Michelle BRADLEY
Michelle BRADLEY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240023522Abstract: A pet amusement device may comprise at least one housing that may comprise, a memory, a power source, a transceiver, and/or at least one sensor. The sensor may be configured to detect one or more parameters corresponding to at least one pet interaction with the device. The device may comprise a processor that may be configured to receive the one or more parameters. The processor may be configured to generate data corresponding to the one or more parameters. The processor may transmit one or more signals corresponding to the data to one or more remote servers. The device may comprise at least one haptic motor configured to generate at least some vibration through the at least one housing. The processor may be configured to control the at least some vibration based on an occurrence of a predetermined condition, or a command from the one or more remote servers.Type: ApplicationFiled: July 25, 2023Publication date: January 25, 2024Applicant: Hill's Pet Nutrition, Inc.Inventors: Susan WERNIMONT, Cheryl STIERS, Janae Michelle BRADLEY, John Michael MCCOY, JR., Robin THOMPSON, Michael Edward MARINELLO, Austin LUGINBILL, Jose Mateus RAITZ PERSCH, Kylie Wilkerson, Aaron STORY
-
Patent number: 11466089Abstract: The present invention relates to polypeptides directed against or specifically binding to C—X—C Motif chemokine receptor 2 (CXCR2) and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: GrantFiled: June 26, 2017Date of Patent: October 11, 2022Assignee: Ablynx N.V.Inventors: Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
-
Patent number: 11278094Abstract: Provided is a document holder having a first wall, a second wall, a top plate, a rear plate, a first divider, and a second divider, where the document holder is configured to interface with a receiving surface. Further, the document holder may include a slider that may traverse a first chamber, a second chamber, and a third chamber, where any of the chambers may include a document. The slider may reversibly conceal the document(s), enabling a third party to view the document(s) from an outside perspective when the slider is removed from the holder.Type: GrantFiled: August 7, 2021Date of Patent: March 22, 2022Inventors: Joseph Griffin, Michelle Bradley
-
Patent number: 10174118Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: GrantFiled: June 26, 2015Date of Patent: January 8, 2019Assignee: Novartis AGInventors: Michelle Bradley, Zarin Brown, Steven John Charlton, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Gino Anselmus Van Heeke
-
Publication number: 20180022811Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: ApplicationFiled: June 26, 2017Publication date: January 25, 2018Applicant: Novartis AGInventors: Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
-
Patent number: 9688763Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: GrantFiled: June 26, 2015Date of Patent: June 27, 2017Assignee: Novartis AGInventors: Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
-
Publication number: 20170101476Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: ApplicationFiled: June 26, 2015Publication date: April 13, 2017Applicant: Novartis AGInventors: Michelle BRADLEY, Zarin BROWN, Steven John CHARLTON, Karen CROMIE, Bruno DOMBRECHT, Soren STEFFENSEN, Gino Anselmus VAN HEEKE
-
Publication number: 20160272714Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: ApplicationFiled: June 26, 2015Publication date: September 22, 2016Inventors: Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
-
Patent number: 9328174Abstract: The present invention relates to polypeptides directed against or specifically binding to CXC chemokine receptor 2 (“CXCR2”) and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: GrantFiled: May 3, 2013Date of Patent: May 3, 2016Assignee: Novartis AGInventors: Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
-
Patent number: 9127067Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: GrantFiled: October 29, 2013Date of Patent: September 8, 2015Assignee: Novartis AGInventors: Michelle Bradley, Steven John Charlton, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Gino Anselmus Van Heeke
-
Publication number: 20140050736Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: ApplicationFiled: October 29, 2013Publication date: February 20, 2014Applicant: NOVARTIS AGInventors: Michelle BRADLEY, Zarin BROWN, Steven John CHARLTON, Karen CROMIE, Bruno DOMBRECHT, Soren STEFFENSEN, Gino Anselmus VAN HEEKE
-
Publication number: 20130330346Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: ApplicationFiled: May 3, 2013Publication date: December 12, 2013Inventors: Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
-
Patent number: 8591896Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: GrantFiled: November 7, 2011Date of Patent: November 26, 2013Assignee: Novartis AGInventors: Michelle Bradley, Zarin Brown, Steven John Charlton, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Gino Van Heeke
-
Publication number: 20120183549Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: ApplicationFiled: November 7, 2011Publication date: July 19, 2012Applicant: NOVARTIS AGInventors: Michelle BRADLEY, Zarin BROWN, Steven John CHARLTON, Karen CROMIE, Bruno DOMBRECHT, Soren STEFFENSEN, Gino VAN HEEKE
-
Patent number: D998035Type: GrantFiled: July 21, 2021Date of Patent: September 5, 2023Assignee: SP Industries LLCInventors: Joseph Griffin, Michelle Bradley